Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Summary of Significant Accounting Policies

Schedule of the items included within net loss regularly provided to the CODM

	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
Revenue	$	19,291	$	20,197	$	38,350	$	38,717
Cost of revenue (excluding amortization of intangible assets)		5,253		5,997		11,697		11,910
Amortization of intangible assets		95		95		190		190
Gross profit		13,943		14,105		26,463		26,617
Sales and marketing:
Sales and sales management		10,165		11,216		20,961		22,830
International		2,062		1,451		4,021		2,808
Other sales and marketing (a)		4,215		4,190		7,997		7,827
Total sales and marketing		16,442		16,857		32,979		33,465
General and Administrative:
Finance and Legal		1,996		1,968		4,022		3,919
Other general and administrative (b)		2,065		2,158		4,205		4,043
Total general and administrative		4,061		4,126		8,227		7,962
Research and Development:
Clinical		1,164		872		2,223		1,780
Regulatory and quality		547		427		1,087		867
Other research and development (c)		1,012		904		1,756		2,096
Total research and development		2,723		2,203		5,066		4,743
Other segment items (d)		(1,979)		(842)		(3,726)		(1,634)
Net loss	$	(11,262)	$	(9,923)	$	(23,535)	$	(21,187)
(a) Other sales and marketing includes strategy, analytics and allocated facility expenses.
(b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses.
(c) Other research and development includes engineering and allocated facility expenses.
(d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, loss on extinguishment of debt, other income and income tax expense.

Schedule of reconciliation of all captions of cash, cash equivalents and restricted cash

	June 30,
	2026		2025
Cash and cash equivalents	$	30,424	$	34,977
Restricted cash		200		265
Total cash and cash equivalents and restricted cash shown in statements of cash flows	$	30,624	$	35,242

Schedule of Disaggregation of Revenue

The following table presents revenue disaggregated by the Company’s portfolio of products (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2026		2025		2026		2025
OviTex	$	13,308	$	12,487	$	25,927	$	24,596
OviTex PRS		5,460		7,333		11,341		13,377
Other		523		377		1,082		744
Total revenue	$	19,291	$	20,197	$	38,350	$	38,717

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
June 30, 2026:
Cash equivalents – money market fund	$	29,279	$	—	$	—
December 31, 2025:
Cash equivalents – money market fund	$	47,068	$	—	$	—

Schedule of dilutive securities excluded

	Six months ended June 30,
	2026	2025
Stock options	3,485,351	2,817,979
Unvested restricted stock units	2,015,615	1,359,116
Common stock warrants	88,556	88,556
Common stock warrants issued with credit agreement	2,000,000	—
Total	7,589,522	4,265,651